Target rounds up YouTube superstars for new series
MINNEAPOLIS — Target is teaming up with four YouTube stars and Veronica Valencia, founder of Design Hunter L.A., on a YouTube video series that combines reality television and design challenges. The series, "Best Year Ever," will give college students tips and tricks that will help them design their own dorm or off-campus living space.
YouTube stars Todrick Hall, Mikey Bolts, Tiffany Garcia and Anne Lee will each host a four-episode series that follows an actual college student as they get ready for living on campus. Valencia will give each room a makeover and provide design solutions. The series will make its debut throughout July and August on each YouTube personality's page and on Target's YouTube channel.
“Target caters to college students who are creating and designing their own space for the first time,” said Rick Gomez, SVP marketing, Target. “We have the right products at great prices, and our video series is full of entertaining inspiration and ideas for stylish, small-space living.”
Some of the top trends for the upcoming back-to-college season include such items as folding bookcases and desks, décor accessories and various lighting accents, according to Target.
Sandoz secures rights for Kerydin
PRINCETON, N.J. — Sandoz on Monday announced an agreement with Anacor Pharmaceuticals to obtain exclusive rights to commercialize Kerydin (tavaborole) topical solution, 5%, through its branded dermatology business, PharmaDerm. Kerydin is an antifungal approved for the treatment of onychomycosis of the toenails.
“Kerydin is an important addition to PharmaDerm’s product portfolio. This agreement provides us with an excellent growth opportunity and reinforces our leadership in the topical dermatology specialty market,” said Peter Goldschmidt, president of Sandoz. “Collaborations in key growth areas that offer potential for further synergies are an important part of our strategy of bringing high-quality, affordable medicines to patients.”
Teva announces successful acquisition of Labrys
JERUSALEM — Teva Pharmaceutical Industries on Monday announced that its acquistion of Labrys has been completed. The acquisition brings to Teva LBR-101, which is currently in phase-2b clinical trials for prevention of chronic and episodic migraines.
“We are pleased to finalize this acquisition. It’s an exciting opportunity to develop a much-needed treatment option for people suffering from the impact of chronic and episodic migraines. The CGRP pathway is scientifically robust, the molecule has the right specifications to deliver on its clinical promise, and the patient population is both large and underserved. This could make a real and meaningful difference to patients’ lives,” said Michael Hayden, Teva’s president of global R&D and chief scientific officer.
The company's acquisition of LBR-101 joins Teva's acquisition of Zecuity, an iontophoretic patch that delivers sumatriptan via the skin and is used for the acute treatment of migraine.